References

Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats.

10.1126/science.281.5381.1349 · 1998 · External reference

Activation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats.

10.1152/jn.00875.2004 · 2005 · External reference

Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects.

10.1007/s00213-004-1982-8 · 2005 · External reference

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial.

10.1038/nm1632 · 2007 · External reference

Glutamate levels in medial prefrontal cortex according to illness phase of never-medicated individuals with psychosis.

10.1001/jamapsychiatry.2025.4091 · 2026 · External reference

Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver.

10.1016/j.neuron.2013.02.011 · 2013 · External reference

Mapping genomic loci implicates genes and synaptic biology in schizophrenia.

10.1038/s41586-022-04434-5 · 2022 · External reference

GRIN2A null variants confer a high risk for early-onset schizophrenia and other mental disorders and potentially enable precision therapy.

10.1038/s41380-025-03279-4 · 2026 · External reference

Grin2a knockout in adolescent dopamine neurons disrupts prediction error signaling and produces a phenotype relevant to schizophrenia.

10.1038/s41380-026-03632-1 · 2026 · External reference

Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2/3 receptor agonist pomaglumetad methionil in schizophrenia.

10.1016/j.biopsych.2015.03.016 · 2015 · External reference